Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.
about
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel diseaseSelective cyclooxygenase 2 inhibitors for the treatment of rheumatological manifestations of inflammatory bowel diseaseRofecoxib for rheumatoid arthritisRofecoxib for osteoarthritisA turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityVariability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysisGastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humansPharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugsEncouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies: protocol of a randomized controlled trial [ISRCTN43532635].TOIB Study. Are topical or oral ibuprofen equally effective for the treatment of chronic knee pain presenting in primary care: a randomised controlled trial with patient preference study. [ISRCTN79353052].Current perspectives in NSAID-induced gastropathyGastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesGuidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapyThe risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of gastroprotective drugsNSAIDs: gastroprotection or selective COX-2 inhibitor?Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groupsNon-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutionsRole of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug usersA nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug useMinidose aspirin and gastrointestinal bleeding--a retrospective, case-control study in hospitalized patientsPractical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDsBalancing the gastrointestinal benefits and risks of nonselective NSAIDs.Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer diseaseInteractions between Helicobacter pylori and other risk factors for peptic ulcer bleedingASS or clopidogrel plus esomeprazole after bleeding from an ulcerManagement of peptic ulcer disease not related to HelicobacterRisk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseasesThe effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosaPrevention and treatment of NSAID-induced gastroduodenal injuryIs there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tractNSAID-induced gastrointestinal damage: current clinical management and recommendations for preventionAdverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tractUnmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseasesPrevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesPrimer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risksIs ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?Iron status and the use of non-steroidal anti-inflammatory drugs in hemodialysis patientsCurrent approaches to prevent NSAID-induced gastropathy--COX selectivity and beyondProton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study
P2860
Q24193086-3F073067-101E-41D2-B8CD-1CB90397D259Q24240479-612D1DFF-4055-4B3A-8F0F-72350E166C4FQ24244836-2100A93C-638A-43CF-8EF5-89A5A8B2EBE7Q24244871-BFED32A9-FE12-451A-895A-5D129CBE3134Q24615651-BEF78439-859A-4CAF-A969-8A18DC855EFDQ24655364-C1385DB5-F78F-47A3-9C06-05B939589891Q24669542-D801B9C7-AB52-4F74-B37B-DB184AFC211BQ24792554-A41F8E56-3629-45E3-B840-9301F11982A1Q24806495-941DB5B1-F725-4C5E-AB70-0EF574B96D14Q24811516-2297C76F-3710-4E07-92EA-0116F2780B79Q26827673-2FD577A1-0023-4349-B89F-F68F25B44D35Q27026351-35A659FA-61F0-4315-8E34-D312D4090E17Q28166768-6CDD0369-7332-4EE8-AF96-92EFE4348731Q28167214-8F188041-6A97-4096-9ADB-245D94034A36Q28168965-659A4F22-6E88-49E1-8B78-74AF4BB78CF1Q28173947-08FD55B0-831B-4073-84F5-F1DE829692DAQ28175347-ECA1E443-0307-46A1-B6D3-D94F796AB496Q28182449-62DA613C-320E-4DB3-B347-7F1CA21A78D5Q28186337-317E11C0-D87B-4849-9C7A-EBCEAC4097D1Q28189998-632579F8-FB66-413C-8194-7281059B355EQ28191928-D7B4BEF0-3D3A-4A4D-8FEC-2DFD4AAC19AEQ28191932-F6690DC0-D370-4FA7-BDB1-45FE8BC2C52DQ28192384-01CA83CD-B58E-4EC1-835C-A9905AF34350Q28192471-4C53C2CF-8530-488B-8522-9DEE56CC936EQ28192619-BCCADA7F-AE0F-4C52-84DE-1ADEF3B8BBBEQ28192901-04347789-6122-4DB8-8157-FD533856B1E3Q28193996-D661D37F-CD28-4E6C-8EDA-976CCADF54E8Q28194351-B01A7892-318B-423A-98C5-6743B7832DB6Q28195728-CADB1DAA-5753-4CB9-8AD6-599A5EEE1D68Q28196511-4BD74172-FF5F-4D58-AF18-89F9770B5F08Q28196933-C413FD44-69D7-4416-AE48-B982A7FE9508Q28198627-2DFFEDA6-761C-46F8-814B-5698D74B630AQ28199102-F313186D-6AFF-46AF-8A39-CC055EF2D33AQ28199775-5068A8F7-57DC-4608-A2CD-2527A84E8DECQ28200569-E036AA73-DF3A-4057-B1CA-42DDA297D1C0Q28200571-7F77A386-F0AD-4753-B650-6C7D2DD3AB6FQ28201393-478A6361-C48B-447B-94E5-9041EF568F46Q28210493-D1B701CB-C762-40DF-B558-0849D08FC0E9Q28210656-CA91B66E-4803-48AE-BEC2-AB46B44B0ED3Q28211313-3A36DE61-AB99-4ED2-91E4-8E2495CA59A2
P2860
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@ast
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@en
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@nl
type
label
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@ast
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@en
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@nl
prefLabel
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@ast
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@en
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@nl
P2093
P921
P1476
Misoprostol reduces serious ga ...... ind, placebo-controlled trial.
@en
P2093
Bittman RM
Silverstein FE
Struthers BJ
P304
P356
10.7326/0003-4819-123-4-199508150-00001
P407
P577
1995-08-01T00:00:00Z